---
layout: default
title: Caffeine Anhydrous
parent: 僅模型預測 (L5)
nav_order: 84
evidence_level: L5
indication_count: 0
---

# Caffeine Anhydrous
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Caffeine Anhydrous: Repurposing Evaluation — Insufficient Data to Generate Prediction

## Summary

Caffeine Anhydrous is a drug compound currently under entry into the TxGNN South Africa repurposing pipeline. No original indication data is recorded in this Evidence Pack, and the TxGNN model has not generated any repurposing predictions for this compound at this time. This report documents the current state of available data and provides guidance on the next steps required before a repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in Evidence Pack |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — Model prediction not yet generated; no supporting studies |
| South Africa Market Status | Not Registered |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction is Available

The TxGNN prediction pipeline requires two inputs to produce a repurposing candidate score: a valid **DrugBank ID** (to locate the drug node in the knowledge graph) and at least one **mapped original indication** (to anchor the drug's starting position in the disease network).

For this submission, both inputs are missing:

- The DrugBank ID for Caffeine Anhydrous was not resolved, despite a successful DrugBank query on 26 March 2026. This may indicate a name-matching failure — "Caffeine Anhydrous" is the anhydrous salt form, whereas DrugBank indexes the compound under **Caffeine** (DB00201). A name normalisation step is needed.
- No original indications are recorded in the Evidence Pack, meaning the pipeline cannot establish a disease anchor for graph traversal.

Until these two gaps are resolved, no TxGNN score, no disease candidates, and no evidence retrieval (clinical trials, literature) can be generated.

---

## South Africa Market Information

Caffeine Anhydrous has **no current SAHPRA registrations**. It is not registered as a standalone product in South Africa at this time.

> **Note:** Caffeine-containing combination products (e.g., analgesic combinations) may hold separate registrations under different active ingredient entries. These would not appear in a search conducted under "Caffeine Anhydrous" and would require a dedicated search under each combination product name.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA via the MedSafety reporting system.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack contains two blocking data gaps — no DrugBank ID resolution and no original indication data — that prevent the TxGNN repurposing pipeline from generating any candidate predictions. There is no actionable repurposing output to evaluate at this stage.

**To proceed, the following is needed:**

1. **Resolve DrugBank ID**: Re-query DrugBank using the normalised name **"Caffeine"** (DB00201) rather than "Caffeine Anhydrous". Confirm whether the anhydrous form shares the same graph node.
2. **Establish original indications**: Retrieve approved indications from the SAHPRA product register or, if absent, from a reference database (DrugBank, WHO INN records, or the British National Formulary).
3. **Retrieve mechanism of action (MOA)**: Query DrugBank API for the pharmacological action of DB00201 to support mechanistic plausibility analysis once predictions are available.
4. **Re-run TxGNN pipeline**: Once DrugBank ID and at least one original indication are confirmed, re-submit to generate repurposing candidates and trigger evidence collection from ClinicalTrials.gov, PubMed, and ICTRP.
5. **Check combination product registrations**: Search the SAHPRA register separately for caffeine-containing combination products to determine actual market presence in South Africa.

> ⚠️ **YMYL Disclaimer:** This report is for research reference purposes only and does not constitute medical advice. Any drug repurposing candidate identified by TxGNN requires clinical validation before therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

